Hepatocellular carcinoma and antidepressants: a nationwide population-based study.
Hepatocellular carcinoma and antidepressants: a nationwide population-based study.
复制标题
DOI：
10.18632/oncotarget.12826
复制
发表时间：
2017-05-02
期刊：
影响因子：
--
通讯作者：
Chan HL
中科院分区：
文献类型：
--
作者：
Chen VC;Lin CF;Hsieh YH;Liang HY;Huang KY;Chiu WC;Lee Y;McIntyre RS;Chan HL
肝细胞癌（HCC）在亚洲非常流行。抗抑郁药与肝细胞癌的增加有关。这是第一项基于亚洲人群的研究，旨在评估抗抑郁药物的使用与肝癌风险之间的关联。我们以台湾国民健康保险研究数据库为基础，进行了全国范围内的人口研究。总共鉴定了 49,998 例 HCC 病例，并与 244,236 例随机选择的对照进行配对。通过调整几个混杂因素的条件逻辑回归模型对数据进行分析。使用三环类抗抑郁药 (TCA) 和选择性血清素再摄取抑制剂 (SSRI) 与较低的 HCC 风险相关。未发现使用其他类别的抗抑郁药与 HCC 之间存在明显关联，包括单胺氧化酶抑制剂 (MAOIs)、5-羟色胺去甲肾上腺素再摄取抑制剂 (SNRI)、曲唑酮、米氮平和安非他酮。 TCA 和 SSRI 对 HCC 的保护作用的研究结果应谨慎解释，并值得进一步研究。
Hepatocellular carcinoma (HCC) is highly prevalent in Asia. Antidepressants have been associated with increase in hepatocellular carcinoma. This is the first Asian population-based study to evaluate the association between antidepressant use and risk of HCC. Based on Taiwans National Health Insurance Research Database, we conducted a nationwide population-based study. A total of 49,998 cases with HCC were identified and paired with 244,236 randomly selected controls. The data was analyzed via the conditional logistic regression model adjusting for several confounding factors. Use of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) was associated with lower risk for HCC. No apparent association was found between use of other classes of antidepressants and HCC, including monoamine oxidase inhibitors (MAOIs), serotonin norepinephrine reuptake inhibitors (SNRIs), trazodone, mirtazapine and bupropion. The findings of a protective effect of TCAs and SSRIs for HCC should be interpreted with caution and warrants further research.